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Sin  Nombre  virus  (SNV;  family  Bunyaviridae,  genus  Hantavirus)  causes  a  hemorrhagic  fever  known  as
hantavirus  pulmonary  syndrome  (HPS)  in  North  America.  There  have  been  approximately  200  fatal  cases
of  HPS  in  the  United  States  since  1993,  predominantly  in  healthy  working-age  males  (case  fatality  rate
35%).  There  are  no  FDA-approved  vaccines  or drugs  to prevent  or  treat  HPS.  Previously,  we reported
that  hantavirus  vaccines  based  on the  full-length  M gene  segment  of Andes  virus  (ANDV)  for  HPS in
South  America,  and  Hantaan  virus  (HTNV)  and  Puumala  virus  (PUUV)  for hemorrhagic  fever with  renal
syndrome  (HFRS)  in  Eurasia,  all  elicited  high-titer  neutralizing  antibodies  in  animal  models.  HFRS  is
more  prevalent  than  HPS  (>20,000  cases  per  year)  but  less  pathogenic  (case  fatality  rate  1–15%).  Here,
we  report  the  construction  and  testing  of a SNV  full-length  M gene-based  DNA  vaccine  to  prevent  HPS.
Rabbits  vaccinated  with  the  SNV  DNA  vaccine  by  muscle  electroporation  (mEP)  developed  high  titers  of
neutralizing  antibodies.  Furthermore,  hamsters  vaccinated  three  times  with  the  SNV  DNA  vaccine  using
a  gene  gun  were  completely  protected  against  SNV  infection.  This  is  the  ﬁrst  vaccine  of  any  kind  that
speciﬁcally  elicits  high-titer  neutralizing  antibodies  against  SNV.  To  test  the  possibility  of  producing  a
pan-hantavirus  vaccine,  rabbits  were  vaccinated  by  mEP  with  an  HPS  mix  (ANDV  and  SNV plasmids),
or  HFRS  mix  (HTNV  and  PUUV  plasmids),  or HPS/HFRS  mix  (all  four  plasmids).  The HPS mix  and  HFRS
mix  elicited  neutralizing  antibodies  predominantly  against  ANDV/SNV  and  HTNV/PUUV,  respectively.
Furthermore,  the  HPS/HFRS  mix elicited  neutralizing  antibodies  against  all four  viruses.  These  ﬁndings
demonstrate  a  pan-hantavirus  vaccine  using  a mixed-plasmid  DNA  vaccine  approach  is  feasible  and
warrants  further  development.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.. Introduction
A 1993 outbreak of acute illness characterized by fever, myalgia,
nd pulmonary failure in the four corners region of the southwest
nited States led to the discovery of Sin Nombre virus (SNV), one
f the etiological agents of hantavirus pulmonary syndrome (HPS)
1–3]. According to the Centers for Disease Control and Prevention,
rom 1993–2012, there have been 586 reported cases of HPS in
Abbreviation: mEP, muscle electroporation.
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Open access under CC BY-NC-SAthe U.S. with a case fatality rate of 35%. SNV is the predominant
hantavirus causing disease in North America including the most
recent HPS outbreak in Yosemite Valley, California [4].
Hantaviruses cause two  unique diseases targeting the lung (HPS)
or the kidney hemorrhagic fever with renal syndrome (HFRS). HPS
is primarily associated with New World hantaviruses (e.g. SNV and
ANDV) found in the Americas, whereas Old World hantaviruses
(e.g. HTNV, PUUV, Seoul virus, and Dobrava-Belgrade virus) cause
HFRS in Europe and Asia [5,6]. There are currently no FDA-approved
vaccines or therapeutics to treat hantavirus disease [7].
Hantaviruses are enveloped viruses with a trisegmented,
negative-sense RNA genome. The S segment encodes for the nucle-
oprotein (N), M segment encodes the Gn and Gc glycoproteins, and
L segment encodes the RNA-dependent RNA polymerase [8]. While
both N and Gn/Gc have been shown to contribute to protective
immunity (reviewed in [7]), only the glycoproteins have been
shown to be the targets of neutralizing antibodies. Moreover,
neutralizing antibodies have been shown to be sufﬁcient to confer
 license.
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rotection in passive transfer experiments using Gn/Gc-speciﬁc
onoclonal and polyclonal antibodies [9–11].
We have previously reported on the construction and efﬁcacy
f gene gun-delivered DNA vaccines targeting HTNV and PUUV M
egment in nonhuman primates, hamsters, and humans in a phase
 clinical trial [12–14]. We  have also reported that an ANDV M
ene-based DNA vaccine, and a plasmid containing both the ANDV
nd HTNV M genes, could elicit high titer neutralizing antibod-
es in rabbits and nonhuman primates when delivered by mEP  or
ene gun [11,15,16]. Others have demonstrated that a N-based or
lycoprotein fragment-based DNA vaccine were capable of elici-
ing detectable neutralizing antibody titers in BALB/c mice (Focus
eduction Neutralization Test80 = 20) and protecting deer mice
gainst infection with SNV in the absence of high titer neutralizing
ntibodies [17,18]. There have been no reports of DNA vaccines,
r any other type of vaccine, capable of eliciting high titer neu-
ralizing antibodies against SNV. In the current study, we  report
n the development, immunogenicity, and protective efﬁcacy of a
ull length M gene-based DNA vaccine to SNV. We  expand on these
ndings and demonstrated the efﬁcacy of multivalent DNA vac-
ines simultaneously targeting the causative agents of both HPS
nd HFRS.
.  Materials and methods
.1.  Viruses, cells, and medium
SNV  strain CC107 [19], ANDV strain Chile-9717869 [20], HTNV
train 76–118 [21], and PUUV strain K27 [22] were propagated
n Vero E6 cells (Vero C1008; ATCC CRL 1586). These cells were
aintained in Eagle’s minimum essential medium with Earle’s salts
ontaining 10% fetal bovine serum, 10 mM HEPES, pH 7.4, and
enicillin Streptomycin (Invitrogen) at 1X, and gentamicin sulfate
50 g/ml) at 37 ◦C in a 5% CO2 incubator.
.2. Animals
Female New Zealand white rabbits (Oryctolagus cuniculus) aged
1 weeks were used in the DNA vaccination studies. Female Syrian
amsters (Mesocricetus auratus) aged 6–8 weeks were used in the
accination/challenge study.
.3. Construction of hantavirus M gene vaccine plasmid
The SNV M gene DNA vaccine plasmid pWRG/SN-M(2a) was
onstructed by reverse transcription of viral RNA, followed by
CR ampliﬁcation of cDNA, and standard cloning techniques.
orward and reverse primers were based on SNV sequences. The
orward primer was SN-Fj (5′-GGCCGCGGCCGCGGATCTGCAGG-
ATTCGGCACGAGAGTAGTAGACTCCGCACGAAGAAGC) and the
everse primer was SN-Mrev (5′-GGCCTTCGAATAGTAGTAGACTCC-
CAGGAAC).  The forward primer included a NotI restriction site
underlined) and the reverse primer included a BstBI restriction
ite (underlined). cDNA was puriﬁed by use of a PCR puriﬁcation
it (Qiagen) and used as a template in PCR. Primers were included
n the PCR mix, which also included Platinum Taq High Fidelity
NA polymerase (Invitrogen); the PCR conditions were one 3-min
ycle at 94 ◦C followed by 30 cycles of 94 ◦C for 30 s and 68 ◦C
or 8 min. The PCR product was cut with NotI and BstBI and then
igated into NotI-BstBI-cut modiﬁed pWRG7077 vector to produce
WRG/SN-M(2a).
To produce an optimized plasmid, the SNV M gene open read-ng frame from pWRG/SN-M(2a) was codon-optimized [23] and
our amino acids were changed to consensus residues based on
lignments with published SNV M genes. The optimized gene was
ynthesized by GeneArt and subcloned into the NotI and BglII sites1 (2013) 4314– 4321 4315
of the DNA vaccine vector pWRG7077, creating pWRG/SN-M(opt).
This plasmid has been submitted to the ATCC, Patent Deposit
Designation PTA-11660. The HTNV M gene DNA vaccine plasmid
is designated as pWRG/HTN-M(x), the PUUV vaccine plasmid is
pWRG/PUU-M(s2), and the ANDV is pWRG/AND-M, they have been
described previously [13,14].
2.4. mEP vaccination
Anesthetized New Zealand white rabbits were vaccinated by
mEP using either the Inovio Elgen delivery device or the Ichor
TriGrid delivery device. DNA vaccination with the Inovio Elgen
delivery device was  conducted as previously described [16]. Each
vaccination session was  a single mEP  event in one leg.
Rabbits vaccinated using the Ichor TriGrid delivery device was
conducted as previously described [24]. The dose of DNA per injec-
tion is provided in ﬁgure legends.
2.5. Gene gun vaccination
Vaccinations using an XR particle-mediated epidermal delivery
device (gene gun) (PowderJect-XR delivery device; PowderJect Vac-
cines, Inc.) have been described previously [13,14,25]. Anesthetized
outbred female Syrian hamsters (6–8 weeks or older) were vacci-
nated with four administrations per vaccination. This procedure is
non-painful with the only adverse effect being mild erythema at
the vaccination site.
2.6.  Challenge with hantavirus
Anesthetized  Syrian hamsters were exposed to SNV or ANDV
by intramuscular (i.m.) injection to the caudal thigh. 200 PFU
SNV (100 ID50) or 200 PFU ANDV (25 LD50) was  diluted in sterile
phosphate-buffered saline (pH 7.4) and administered in a volume
of 0.2 ml.
2.7.  PRNT
Plaque-reduction neutralization tests (PRNT) were performed
using Vero E6 as previously described [14]. The 50% (or 80%) PRNT
titer (PRNT50 or PRNT80 titer) was the highest serum dilution reduc-
ing the number of plaques by 50% (or 80%) relative to the average
number of plaques in control wells that received medium alone.
For most of the experiments in this report, and in previous studies,
we have reported PRNT50 titers because this gives the highest level
of sensitivity when evaluating vaccines for the ﬁrst time in vivo.
PRNT80 titers are more stringent and are used when sensitivity is
less important than obtaining a conservative determination of the
neutralizing antibody titer.
2.8. N-speciﬁc ELISA
The  enzyme-linked immunosorbent assay (ELISA) used to
detect N-speciﬁc antibodies (N-ELISA) was  described previously
[14,25,26]. The endpoint titer was  determined as the highest dilu-
tion that had an optical density (OD) greater than the mean OD
for serum samples from negative-control wells plus 3 standard
deviations. The PUUV N antigen was  used to detect SNV N-speciﬁc
antibodies as previously reported [22].
2.9. EthicsAnimal research was  conducted under an IACUC approved pro-
tocol at USAMRIID (USDA Registration Number 51-F-00211728 &
OLAW Assurance number A3473-01) in compliance with the Ani-
mal  Welfare Act and other federal statutes and regulations relating
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Fig. 1. Hantavirus neutralizing antibodies produced in rabbits vaccinated with full-length hantavirus M gene-based DNA vaccines using mEP. Groups of 3 rabbits were
vaccinated with DNA vaccines (A) pWRG/HTN-M(x) and (B) pWRG/PUU-M(s2) on days noted by black arrows by mEP (Inovio Elgen device, dose 0.4 mg DNA per injection).
Sera collected were tested in homotypic PRNT. Symbols represent the mean of two separate PRNT50 ± SE. (C) The same data from (A) and (B) were combined to show mean
titers for the groups. Previously published mean titers from rabbits vaccinated with pWRG/AND-M were shown for comparison. Note the vaccination days were different for
the  Andes DNA vaccine (shown in gray arrows). Groups of 3 or 4 rabbits were vaccinated with (D) the ﬁrst generation SNV M gene-based DNA vaccine, pWRG/SN-M(2a) or
(  by b
( ate va
p
t
t
f
n
a
2
t
n
w
3
3
n
u
a
t
p
A
S
w
t
t
t
c
pE)  the optimized SNV M gene-based DNA vaccine, pWRG/SN-M(opt), on days noted
D)  and (E) were combined to show mean titers for the groups. Black arrows indic
WRG/SN-M(opt). The PRNT limit of detection was  a titer of 20 (dashed lines).
o animals and experiments involving animals. The facility where
his research was conducted is fully accredited by the Association
or Assessment and Accreditation of Laboratory Animal Care, Inter-
ational and adheres to principles stated in the Guide for the Care
nd Use of Laboratory Animals, National Research Council, 2011.
.10.  Statistical analysis
Comparison  of neutralizing titers was done using Student’s t
est (two-tailed). P values of less than 0.05 were considered sig-
iﬁcant. Survival analyses were done using log-rank test. Analyses
ere conducted using GraphPad Prism (version 5).
.  Results
.1. Individual hantavirus M-gene-based DNA vaccines elicited
eutralizing antibodies when delivered by mEP in rabbits
Groups of three rabbits were vaccinated four times by mEP
sing pWRG/HTN-M(x) and pWRG/PUU-M(s2), and neutralizing
ntisera titers were determined by plaque reduction neutraliza-
ion test (PRNT) (Fig. 1A and B). A comparison with previously
ublished titers produced in rabbits by mEP  vaccination with an
NDV full-length M segment was included in Fig. 1C. Similarly, a
NV full-length M gene segment DNA vaccine, pWRG/SN-M(2a),
as immunogenic in rabbits but only after three or four vaccina-
ions (Fig. 1D) indicating this plasmid was less immunogenic than
he HTNV, PUUV, or ANDV [16] vaccines. An optimized version of
he SNV M gene open reading frame was synthesized and sub-
loned into the DNA vaccine vector to produce pWRG/SN-M(opt).
WRG/SN-M(2a) and pWRG/SN-M(opt) M genes are identicallack arrows. Sera collected were tested in homotypic PRNT. (F) The same data from
ccination days for pWRG/SN-M(2a) and gray arrows indicate vaccination days for
except  for the open reading frame where optimization resulted in
980/3423 (29%) nucleotide changes and four amino acid changes:
Q27K, A241T, G434D, P519S, where the ﬁrst letter is the symbol for
the amino acid in the product from pWRG/SN-M(2a), the number
is the amino acid position, and the second letter is the amino acid
in the product from pWRG/SN-M(opt). pWRG/SN-M(opt) elicited
high-titer (>10,000) neutralizing antibodies after mEP  detectable
in sera on day 56, after two vaccinations (Fig. 1E). The mean PRNT
titers produced by the two SNV DNA vaccines were plotted to illus-
trate the increased immunogenicity of the optimized SNV M gene
plasmid to the original plasmid (Fig. 1F).
3.2. Immunogenicity of combination DNA vaccines targeting
causative agents of HPS, HFRS, and HFRS/HPS
We next determined if the plasmids could be combined to pro-
duce vaccines eliciting speciﬁc neutralizing antibody responses
against multiple hantaviruses causing HFRS (HTNV and PUUV), HPS
(ANDV and SNV) and a combination targeting both HFRS and HPS
agents (HTNV, PUUV, ANDV, and SNV). Groups of three rabbits were
vaccinated with combinations of DNA vaccines targeting HFRS, HPS
or HFRS/HPS delivered by mEP. Sera were collected, and neutral-
izing antibody titers were determined by SNV, ANDV, HTNV, and
PUUV PRNT. Titers at different time points for individual rabbits
(Fig. 2A), and mean titers for the groups (Fig. 2B), were plotted.
All but one of the rabbits (#6320) developed homotypic neutral-
izing antibody responses after a single vaccination, and all were
positive after the ﬁrst boost. Additionally, both the HFRS and HPS
DNA vaccines elicited some level of cross-neutralization against the
HPS or HFRS hantavirus, respectively, based on geometric mean
titers (GMT) for the PRNT80 values after a single vaccination in
J.W. Hooper et al. / Vaccine 31 (2013) 4314– 4321 4317
Fig. 2. Single-injection multiagent hantavirus DNA vaccines are feasible by mEP. Three mixtures of hantavirus DNA vaccine plasmids were delivered to rabbits by mEP
(Ichor Tri-grid). Groups of 3 rabbits were vaccinated at 3-week intervals and sera were collected for PRNT analysis. The HFRS mixture was comprised of equal volumes of
pWRG/HTN-M(x) and pWRG/PUU-M(s2), (2 mg  DNA total, 1 mg/plasmid/injection, 1 injection/vaccination). The HPS mixture was comprised of equal volumes of pWRG/AND-
M  and pWRG/SN-M(opt) (2 mg DNA total, 1 mg/plasmid/injection, 1 injection/vaccination). The HFRS/HPS mixture was comprised of equal volumes of HTNV, PUUV, ANDV,
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sed  in the neutralization test is shown on the y-axis. (B) Mean neutralization titer
ll by one rabbit (Fig. 3). Nevertheless, the highest SNV and ANDV
ean titers were found in the HPS vaccine and the HFRS/HPS vac-
ine groups, and the highest HTNV and PUUV mean titers were
ound in the HFRS vaccine and HFRS/HPS vaccine groups. These
ata demonstrate that it is possible to mix  hantavirus DNA vaccines
nto a single-injection vaccine and produce neutralizing antibodies
gainst multiple hantaviruses. The neutralizing antibody titers did
ot signiﬁcantly vary between the HFRS or HPS bivalent vaccines
nd the HFRS/HPS quadravalent combination (p > 0.05) indicating
ittle interference between the targets in the larger combination
accine.
SNV M gene-based DNA vaccine delivered by gene gun protects
amsters against SNV infection, but not lethal disease caused by
NDV. Currently, there is no animal model for disease caused
y SNV, but there are models of SNV infection. Syrian hamsters
njected with a dose as low as 2 PFU become infected with SNV
s measured by seroconversion to the N protein [20]. Because
he M gene-based DNA vaccines do not include the N protein, it
s possible to monitor the development of anti-N antibodies as a
easure of productive infection. To determine if our SNV vaccineination). (A) Neutralizing antibody titers for individual rabbits are shown. The virus
ach group ± SE. The PRNT limit of detection was  a titer of 20 (dashed lines).
was  protective, groups of 7–8 hamsters were vaccinated by gene
gun with pWRG/SN-M(opt) or a negative control plasmid either
two times (0 and 3 weeks), three times (0, 3, and 6 weeks) or were
not vaccinated at all. Neutralizing antibody titers were determined
at 0, 3, 6, and 9 weeks by PRNT (Fig. 4A). pWRG/SN-M(opt) was
immunogenic in hamsters, however, antibody titers were lower
than rabbits vaccinated by mEP. After two  vaccinations, a statis-
tically signiﬁcant antibody response was  observed compared to
negative control DNA vaccination group (p = 0.0026 and p = 0.0112,
respectively). Titers increased after a third vaccination (week 9
sera), but this increase was not statistically signiﬁcant (Fig. 4B).
To  evaluate the protective efﬁcacy of the SNV DNA vaccine (5
weeks after the last vaccination), hamsters were challenged with
SNV and were then monitored for seroconversion by N-ELISA. Anal-
ysis of sera collected four weeks after challenge revealed 5 of
8 hamsters receiving two vaccinations were protected from SNV
infection (62.5%, p = 0.0392 when compared to negative control
DNA vaccination group), 7 of 7 hamsters receiving three vac-
cinations were protected from SNV infection (100%, p = 0.0008
when compared to negative control DNA vaccination group), and
4318 J.W.  Hooper et al. / Vaccine 3
Fig. 3. PRNT80 GMT  against HTNV, PUUV, ANDV, and SNV for each DNA vaccine
formulation  after 1, 2, or 3 vaccinations. These data are from the same experiment
shown  in Fig. 2; however, PRNT80 GMT  are presented (A) after 1 vaccination, (B)
after 2 vaccinations, and (C) after 3 vaccinations. The PRNT limit of detection was
a
w
p
n
w
p
n
v
c
m
l
[
i
u
c
c
3
t titer of 20 (dashed lines). ns indicates a lack of statistical signiﬁcance when titers
ere compared from HFRS or HPS mix  to HFRS/HPS mix  vaccine. Signiﬁcance lines
ertain to (A), (B), and (C).
o hamsters receiving negative control DNA or left unvaccinated
ere protected from SNV infection (Fig. 4C). This indicated that
WRG/SN-M(opt) could protect hamsters against SNV but required
eutralizing antibody titers equivalent to those produced by three
accinations.
We next hypothesized that this vaccine would be capable of
ross-protecting against ANDV infection in the hamster disease
odel. Unlike SNV, ANDV infection of Syrian hamsters causes a
ethal endothelium-leak disease that closely resembles human HPS
20]. To test this, 8 hamsters were vaccinated 3 times at 3-week
ntervals with pWRG/SN-M(opt) using gene gun. A group of 7
nvaccinated hamsters served as a negative control for the ANDV
hallenge. Five weeks after the last vaccination, hamsters were
hallenged with 200 PFU of ANDV by the i.m. route (25 LD50). Only
 of 8 hamsters vaccinated with pWRG/SN-M(opt) survived despite
he presence of SNV neutralizing antibodies in 6 of 8 hamsters1 (2013) 4314– 4321
(group  GMT  = 135, p = 0.0045 when compared to no vaccine con-
trols) (Fig. 5B). One of 7 hamsters survived in the negative control
group (p = 0.3108) (Fig. 5A). Results of an ANDV PRNT demonstrated
that sera from vaccinated hamsters had little cross-neutralization
activity (data not shown). Thus, the antibody response elicited by
the SNV DNA vaccine failed to confer statistically signiﬁcant pro-
tection against ANDV.
4.  Discussion
SNV-associated HPS is a serious and unpredictable public health
threat, as afﬁrmed by the 2012 outbreak at Yosemite National Park,
CA [4] that resulted in 3 fatalities and more than 260,000 park vis-
itors potentially exposed to a lethal virus. Here, we  present the
construction, immunogenicity, and protective efﬁcacy of a novel
SNV DNA vaccine designated pWRG/SN-M(opt). To our knowledge,
this is the ﬁrst SNV vaccine of any kind that has been shown to
elicit high-titer neutralizing antibodies (i.e., PRNT50 > 1000). The
antibody response elicited by pWRG/SN-M(opt) is among the most
potent per vaccination ever achieved with a hantavirus DNA vac-
cine. One to two vaccinations with pWRG/SN-M(opt) plasmid alone
using mEP  resulted in SNV PRNT50 titers as high as 40,280, and one
vaccination with the combined SNV and ANDV plasmids resulted in
SNV PRNT titers as high as 20,480. The PRNT80 GMT  for rabbits vac-
cinated one or two  times with pWRG/SN-M(opt) was  5120. These
PRNT80 titers were higher than those reported for HPS survivors
[27]. Studies were not performed to elucidate which of the 980
nucleotide and/or four amino acid changes improved the immuno-
genicity of the SNV DNA vaccine. We  speculate that a combination
of changes resulted in improved vaccine quality (e.g., plasmid sta-
bility, plasmid yield) and vaccine immunogenicity (e.g., mRNA
stability, efﬁciency of expression, and protein folding). Neutralizing
antibodies are not required for protection; however, we and others
have shown that neutralizing antibodies are sufﬁcient to protect
[10,11,16,28–31]. Thus, a hantavirus vaccine capable of eliciting
a potent neutralizing antibody response is an excellent candidate
for evaluation as a SNV vaccine (e.g., Phase 1 clinical trials) and a
means to produce a neutralizing antibody-based immunoprophy-
lactic/therapeutic.
Hantaviruses are a neglected worldwide infectious disease
problem and it would be beneﬁcial to have a single vaccine
capable of protecting against multiple pathogenic hantaviruses.
This would reduce the burden of developing speciﬁc vaccines for
the myriad different pathogenic hantaviruses around the world.
Combinations of plasmids co-delivered separately or delivered
as mixtures shows promise in animal models [15,32]. Data from
these studies have demonstrated that DNA vaccines can also elicit
cross-protection against other species of hantaviruses [13,14]. This
cross-neutralizing activity appears to be highly variable and can
depend on the vaccine, the route of delivery, the species, and the
individual. For example, in nonhuman primates, the ANDV DNA
vaccine elicited antibodies that demonstrated a high level of cross-
neutralizing activity against SNV [15]. However, the same vaccine
delivered to rabbits failed to elicit SNV cross-neutralizing antibod-
ies [16]. Similarly, a combination of ANDV and HTNV M genes was
capable of eliciting cross neutralizing antibodies against both HPS
and HFRS hantaviruses in nonhuman primates; but titers were low
[15]. Here, we  tested the possibility of combining SNV and ANDV
plasmids, PUUV and HTNV plasmids, or a combination of all four
plasmids delivered by mEP in rabbits. We  found that the HPS vac-
cine elicited potent responses against both SNV and ANDV, but
not HTNV or PUUV. Conversely, the HFRS vaccine elicited a potent
response against both HTNV and PUUV but not ANDV or SNV. When
all four plasmids were combined, comparable levels of neutralizing
antibody titers relative to the HPS or HFRS vaccines were produced
J.W. Hooper et al. / Vaccine 31 (2013) 4314– 4321 4319
Fig. 4. pWRG/SN-M(opt) DNA vaccine (gene gun) is immunogenic and protective in hamsters. Groups of 7–8 hamsters received 2 or 3 vaccinations with the pWRG/SN-M(opt)
SNV DNA vaccine, 3 vaccinations with a negative control DNA vaccine, or no vaccine. (A) Sera collected were tested for SNV neutralizing antibodies by PRNT. Mean titers ± SE
are  shown. (B) Individual PRNT50 titers from sera collected on week 9 are presented with the GMT  and 95% conﬁdence interval depicted. The PRNT limit of detection was
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egative by ELISA (data not shown).<indicates titer was  below level of detection for
egative  DNA vaccination controls.
gainst all four hantaviruses (Fig. 3). Given the importance of neu-
ralizing antibodies in protection [9–11], the levels achieved with
he quadravalent vaccine suggest it will protect against ANDV, SNV,
UUV, and HTNV.
Previous  studies using gene gun technology to administer the
TNV/PUUV DNA vaccines in hamsters has shown signiﬁcantly
educed anti-HTNV neutralizing antibody responses when the plas-
ids were mixed [32]. Interestingly, this interference was  not
bserved if the HTNV and PUUV were delivered separately or
hen coated on different gold particles before delivery. While the
echanism is unknown, it is likely the interference occurs when
he different plasmids are expressing the Gn/Gc proteins in the
ame cells. The data in Figs. 2 and 3 indicate that the anti-PUUV
esponse was higher than the anti-HTNV responses and the anti-
NV response was higher than the anti-ANDV response. Despite
his apparent dominance, the anti-HTNV and anti-ANDV responses
ere still impressive. Dominance of the PUUV and SNV plasmids
ver the HTNV and ANDV plasmid, respectively, could reﬂect the
dvantages of optimization because neither the HTNV nor ANDV
accines used in this study were codon optimized.
To investigate the efﬁcacy of the optimized SNV DNA vaccine,
e used the Syrian hamster infection model. This model and a deer
ouse infection model are the only systems available to evaluate
rotection against SNV [33,34]. For these studies, we used gene gun
elivery since a gene gun had been previously shown to successfully
eliver HTNV and PUUV DNA vaccines to hamsters and humanstested by ELISA for evidence of SNV infection. All prechallenge sera samples were
say. *indicates antibody responses were statistically signiﬁcant when compared to
[12].  In addition, we  were interested in demonstrating that the
pWRG/SN-M(opt) vaccine could be effectively delivered using dif-
ferent delivery technologies. We  found that the pWRG/SN-M(opt)
vaccine was  immunogenic in hamsters, although the titers were
signiﬁcantly lower than those achieved in rabbits (with orders of
magnitude more DNA) using mEP. Despite lower titers, hamsters
were still protected from SNV infection. In contrast, despite ANDV
cross-neutralizing antibodies elicited by mEP  in rabbits (Fig. 2),
hamsters vaccinated with pWRG/SN-M(opt) did not cross-protect
against ANDV disease (Fig. 4).
The experiments reported here consist of a ﬁrst-look at the
SNV DNA vaccine, and combinations thereof. These experiments
involved different animals species (i.e., rabbits and hamsters), DNA
doses (i.e., micrograms to milligrams), vaccination schedules (i.e.,
2-, 3-, or 4-week intervals), and delivery technologies (i.e., gene
gun and two types of muscle electroporation). Although no sin-
gle experiment directly compared how changing these parameters
affected immunogenicity, our ﬁndings that all of these vaccination
conditions resulted in the production of neutralizing antibodies
demonstrate the robustness of the SNV DNA vaccine. Future studies
will directly test how dose, schedule, and device affect the quantity,
quality, and duration of the immune responses.The present report demonstrates active protection against SNV
infection in hamsters. Protection following vaccination with the
mulit-valent hantavirus vaccines was not tested. Previous ﬁnd-
ings that hantavirus neutralizing antibodies are sufﬁcient to protect
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Fig. 5. pWRG/SN-M(opt) DNA vaccine (gene gun) does not protect hamsters from
ANDV challenge. A group of 8 hamsters received 3 vaccinations with pWRG/SN-
M(opt).  (A) Vaccinated and unvaccinated hamsters were challenged with 200 PFU
ANDV i.m. and observed for survival. (B) Sera collected prechallenge were tested by
SNV PRNT for homotypic neutralizing antibodies. The PRNT limit of detection was
a titer of 20 (dashed lines). *indicate antibody response was  statistically signiﬁcant
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[19] Schmaljohn AL, Li D, Negley DL, Bressler DS, Turell MJ, Korch GW,  et al. Isolationhen  compared to no vaccine controls. s indicates the PRNT titer of a surviving
amster.
hould allow a passive approach to efﬁcacy testing involving active
accination of one species followed by passive transfer of immu-
ity to animal models of infection and/or disease. For example, sera
rom rabbits, nonhuman primates, or even humans vaccinated with
he multivalent hantavirus vaccines could be tested for a capac-
ty to protect hamsters against infection and/or disease caused by
NV, ANDV, PUUV, and HTNV. A limitation to a passive transfer
pproach is that it only evaluates the protection conferred by the
umoral immune response. Although neutralizing antibodies have
een shown to be sufﬁcient to protect, there is a recent exam-
le of hantavirus DNA vaccines protecting against disease in the
bsence of detectable neutralizing antibodies. The PUUV DNA vac-
ine protected hamsters against lethal disease caused by ANDV in
he absence of neutralizing antibodies [13]. Here, we found the
NV DNA vaccine did not protect hamsters against lethal disease
aused by ANDV suggesting the cell-mediated immune response
licited by the PUUV DNA vaccine is more cross-reactive with epi-
opes on the ANDV glycoproteins than the SNV DNA vaccine. Thus, if
he passive transfer approach to efﬁcacy testing proves inadequate
o evaluate protection and cross-protection against hantaviruses,
hen it will be necessary to develop new animal models of HPS and
FRS that allow direct efﬁcacy testing of mono- and multi-valent
antavirus vaccines.
This  report is the ﬁrst to describe a SNV vaccine capable of
liciting high-titer neutralizing antibodies, and protection, in
nimal models. We  demonstrated the feasibility of combining this
accine with other hantavirus vaccines to expand the breadth of
eutralizing activity. Current treatment for hantavirus disease
s strictly supportive care [35,36]. But the endemic and episodic
mergence of lethal HPS and HFRS warrants the development of a
[1 (2013) 4314– 4321
direct countermeasure to prevent disease caused by infection with
SNV and other hantaviruses around the world.
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